MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles

MedicaMundi

Volumn 54, Issue 2, 2010, Pages 5-13

  Caruthers, S D ^a   Winter, P M ^a   Wickline, S A ^a   Lanza, G M ^a   Keupp, J ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b PHILIPS RESEARCH LABORATORIES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; FLUOROCARBON; FUMAGILLIN; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NANOPARTICLE; PERFLUOROOCTYL BROMIDE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; ATHEROSCLEROSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMAGE ANALYSIS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE ANALYSIS; SIGNAL DETECTION; TREATMENT RESPONSE;

EID: 78049506162     PISSN: 00257664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Pettigrew RI, Fee CA, Li KC. Changes in the World of Biomedical Research are Moving the Field of "Personalized Medicine" From Concept To Reality. J Nucl Med. 2004; 45(9): 1427.
2. Molecular Imaging: The Road Ahead. Medicamundi. 2003; 47(1). http://www.philips.com/medicamundi
3. Lanza GM, Lamerichs R, Caruthers S, Wickline SA. Molecular Imaging in MR with Targeted Paramagnetic Nanoparticles. Medicamundi. 2003; 47(1): 34-39.
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial Sequencing and Analysis of the Human Genome. Nature. 2001; 409(6822): 860-921.
5. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall Superparamagnetic Iron Oxide: An Intravenous Contrast Agent for Assessing Lymph Nodes with MR Imaging. Radiology. 1990; 175(2): 494-8.
6. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, Van De Kaa CH, et al. Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer. N Engl J Med. 2003; 348: 2491-2499.
7. Gaffney PJ, Gascoine PS, Creighton LJ, Tymkewycz PM. Monoclonal Antibodies for the Detection of Thrombosis. Adv Exp Med Biol. 1990; 281: 419-27.
8. Britz-Cunningham SH, Adelstein SJ. Molecular Targeting with Radionuclides: State of the Science. J Nucl Med. 2003; 44(12): 1945-61.
9. Lipinski MJ, Fuster V, Fisher EA, Fayad ZA. Technology Insight: Targeting of Biological Molecules for Evaluation of High-Risk Atherosclerotic Plaques with Magnetic Resonance Imaging. Nat Clin Pract Cardiovasc Med. 2004; 1(1): 48-55.
10. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 Specific Tumor Targeting with Dendrimer Conjugated Anti-HER2 mAb. Bioconjug Chem. 2006; 17(5): 1109-1115.
11. Lanza G, Wallace K, Scott M, Cacheris W, Abendschein D, Christy D, et al. A Novel Site-Targeted Ultrasonic Contrast Agent with Broad Biomedical Application. Circulation. 1996; 94: 3334-3340.
12. Flacke S, Fischer S, Scott M, Fuhrhop R, Allen J, McLean M, et al. A Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques. Circulation. 2001; 104: 1280-1285.
13. Lanza G, Lorenz C, Fischer S, Scott M, Cacheris W, Kaufman R, et al. Enhanced Detection of Thrombi with a Novel Fibrin-Targeted Magnetic Resonance Imaging Agent. Acad Radiol. 1998; 5(Suppl 1): S173-S176.
14. Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, et al. High-Resolution MRI Characterization of Human Thrombus Using a Novel Fibrin-Targeted Paramagnetic Nanoparticle Contrast Agent. Magn Reson Med. 2000; 44(6): 867-872.
15. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, et al. Quantitative "Magnetic Resonance Immunohistochemistry" with Ligand-Targeted (19)F Nanoparticles. Magn Reson Med. 2004; 52(6): 1255-1262.
16. Makowski MR, Indermeule A, Andia M, Jansen CHP, Botnar RM, Wiethoff AJ, et al. Molecular MRI of Atherosclerosis: From Mouse to Man. Medicamundi 2010; 54(2): xx-yy.
17. Moulton KS. Plaque Angiogenesis: Its Functions and Regulation. Cold Spring Harb Symp Quant Biol. 2002; 67: 471-482.
18. Krupinski J, Font A, Luque A, Turu M, Slevin M. Angiogenesis and Inflammation in Carotid Atherosclerosis. Front Biosci. 2008; 13: 6472-6482.
19. Wu I, Moses MA. Angiogenic Molecules and Mechanisms in Breast Cancer. Curr Oncol Rep. 2000; 2(6): 566-571.
20. Eliceiri BP and Cheresh DA. Role of Alpha V Integrins During Angiogenesis. Cancer J. 2000; 6 Suppl 3: S245-249.
21. Kerr JS, Mousa SA, Slee AM. Alpha(V)Beta(3) Integrin in Angiogenesis and Restenosis. Drug News Perspect. 2001; 14(3): 143-150.
22. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, et al. Magnetic Resonance Contrast Enhancement of Neovasculature with Alpha(V)Beta(3)-Targeted Nanoparticles. Magn Reson Med. 2000; 44(3): 433-9.
23. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis with Alpha(V)Beta3-Integrin-Targeted Nanoparticles. Circulation. 2003; 108(18): 2270-2274.
24. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular Imaging of Angiogenesis in Nascent Vx-2 Rabbit Tumors Using a Novel Alpha(Nu)Beta3-Targeted Nanoparticle and 1.5 Tesla Magnetic Resonance Imaging. Cancer Res. 2003; 63(18): 5838-5843.
25. Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, et al. Minute Dosages of Alpha(Nu)Beta3-Targeted Fumagillin Nanoparticles Impair Vx-2 Tumor Angiogenesis and Development in Rabbits. Faseb J. 2008; 22(8): 2758-2767.
26. Schmieder AH, Williams TA, Allen JS, Hu G, Zhang H, Caruthers SD, et al. Time-Resolved Molecular Imaging of the "Angiogenic Switch" in Animal Models of Cancer. In: Proc Intl Soc Mag Reson Med. 2008: 14.
27. 1H Imaging for Quantification: Calibration and Sensitivity Assessment. In: Proc Intl Soc Mag Reson Med. 2007: 1334.
28. 1H Radial MRI. In: Proc Intl Soc Mag Reson Med. 2008: 17.
29. 1H 3D Radial Imaging Using Golden Means Profile Interleaving. In: Proc Intl Soc Mag Reson Med. 2008: 1471.
30. Keupp J, Caruthers SD, Rahmer J, Williams TA, Wickline SA, and Lanza GM. Fluorine-19 MR Molecular Imaging of Angiogenesis On Vx-2 Tumors in Rabbits Using avß3 Targeted Nanoparticles. In: Proc Intl Soc Mag Reson Med. 2009: 223.
31. 1H Simultaneous 3D Radial Imaging of Atherosclerotic Rabbits Using Self-Navigated Respiratory Motion Compensation. In: Proc Intl Soc Mag Reson Med. 2009: 4611.
32. Woods M, Woessner DE, Sherry AD. Paramagnetic Lanthanide Complexes As PARACEST Agents for Medical Imaging. Chem Soc Rev. 2006; 35(6): 500-511.
33. Zhang S, Merritt M, Woessner DE, Lenkinski RE, Sherry AD. PARACEST Agents: Modulating MRI Contrast via Water Proton Exchange. Acc Chem Res. 2003; 36(10): 783-790.
34. Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ, et al. In Vitro Demonstration Using 19F Magnetic Resonance To Augment Molecular Imaging with Paramagnetic Perfluorocarbon Nanoparticles At 1.5 Tesla. Invest Radiol. 2006; 41(3): 305-312.
35. Guzman LA, Labhasetwar V, Song C, Jang Y, Lincoff AM, Levy R, et al. Local Intraluminal Infusion of Biodegradable Polymeric Nanoparticles. A Novel Approach for Prolonged Drug Delivery After Balloon Angioplasty. Circulation. 1996; 94(6): 1441-1448.
36. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, et al. Sustained Reduction of In-Stent Neointimal Growth with the Use of a Novel Systemic Nanoparticle Paclitaxel. Circulation. 2002; 106(10): 1195-1198.
37. Muller RH, Radtke M, Wissing SA. Nanostructured Lipid Matrices for Improved Microencapsulation of Drugs. Int J Pharm. 2002; 242(1-2): 121-128.
38. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, et al. Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells with a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis. Circulation. 2002; 106(22): 2842-2847.
39. Crowder KC, Hughes MS, Marsh JN, Barbieri AM, Fuhrhop RW, Lanza GM, et al. Sonic Activation of Molecularly-Targeted Nanoparticles Accelerates Transmembrane Lipid Delivery to Cancer Cells through Contact-Mediated Mechanisms: Implications for Enhanced Local Drug Delivery. Ultrasound Med Biol. 2005; 31(12): 1693-1700.
40. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, et al. Endothelial Alpha(V)Beta3 Integrin-Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26(9): 2103-2109.
41. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipoprotein E-Deficient Mice. Circulation. 1999; 99(13): 1726-1732.
42. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth. Nature. 1990; 348(6301): 555-557.
43. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Jr., Meyers CA, Seabrooke LF, et al. Safety and Pharmacokinetic Effects of TNP-470, An Angiogenesis Inhibitor, Combined with Paclitaxel in Patients with Solid Tumors: Evidence for Activity in Non-Small- Cell Lung Cancer. J Clin Oncol. 2002; 20(22): 4440-4447.
44. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis. JACC: Cardiovascular Imaging. 2008; 1(5): 624.
45. Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, et al. Three-Dimensional MR Mapping of Angiogenesis with a5ß1(avß3)-Targeted Theranostic Nanoparticles in the MDA-MB-435 Xenograft Mouse Model. Faseb J. 2008; 22: 4179-4189.
46. Schmieder AH, Winter PM, Williams TA, Allen JS, Hu G, Zhang H, et al. MR Molecular Imaging of Neovasculature may Predict Response to Antiangiogenic Therapy in Animal Cancer Models. In: Proc Intl Soc Mag Reson Med. 2008: 799.